

November 14, 2025

Cain Brothers Industry Insights

Healthcare Market Report



Banker Commentary:

Key Takeaways from ASRM

Banker Commentary

Contents

- Banker Commentary
- M&A Activity
- Private Placements
- Equity Capital Markets
- Public Equity Indices
- High Grade, High Yield & Leveraged Loans
- Public Finance Market
- Relevant News
- Recent Cain Brothers Transactions



Key Takeaways from ASRMBanker Commentary by Stacy Guffanti

Last week, I attended the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo in San Antonio, Texas. This is one of the largest annual gatherings in the fertility industry in the U.S. and is largely

attended by fertility clinics and provider networks, fertility benefit managers, providers (REIs, embryologists, genetic counselors, nurses), industry suppliers (pharma, MedTech, cryobanks), and other vendors within the fertility ecosystem. After visiting busy exhibit halls and having conversations with a diverse group of industry participants, there were some interesting takeaways coming out of the conference.

Significant Buzz Around Potential Impact of President Trump's Recent IVF Policy Proposal

- o President Trump's Proposal¹: On October 16, 2025, President Trump announced actions to lower costs and expand access to in vitro fertilization (IVF) and high-quality fertility care. This included (1) bringing most-favored-nation drug pricing to fertility, (2) expediting FDA review of new fertility drugs to deliver lower costs, and (3) expanding coverage for fertility benefits by issuing guidance to allow employers to offer standalone fertility benefits, similar to how dental and vision benefits are structured.
- o *Potential Impacts:* While there continues to be uncertainty as the policy is still taking shape, this is a positive step towards increasing access to fertility treatment. There is potential for meaningful cost reduction through lower cost drugs. Fertility medication, for example, represents, on average, \$6,000 of an approximately \$20,000 IVF cycle.² Under President Trump's proposal, the Centers for Medicare and Medicaid Services (CMS) estimates that families can save up to \$2,200 per cycle on fertility drugs.³ While this could put pressure on pharma manufacturers, fertility benefit managers and IVF clinics could see a positive net impact through higher volumes. However, this will depend on how many employers choose to offer fertility benefits, as it remains voluntary, and the adoption rate is uncertain. Today, in the U.S., IVF is covered by 70% of jumbo employers and 47% of large employers, up from 62% and 45%, respectively, last year.⁴ President Trump's proposal could enable broader IVF coverage among medium and small employers through the standalone excepted benefit route, as these employers have historically struggled to provide IVF coverage due to the high cost and administrative complexity.

Increasing Number of Fertility/ReproTech Startups

o This year, ASRM launched its inaugural ASRM INNOVATE meeting, designed to bring together industry participants, thought leaders, and innovators to help drive advancements in reproductive medicine through cutting-edge science and technology. Many startups showcased their solutions in the ASRM exhibit hall, and the energy was real. Companies spanned the broader fertility ecosystem and included male fertility diagnostics, fertility financing, lab automation, Al-driven diagnostics and embryo selection, virtual care, cryobanking infrastructure (storage, tracking, logistics), fertility benefits, and at-home treatments and monitoring solutions,

continued...

to name a few. The fertility industry needs innovation, and we expect more investment into fertility and reprotech. However, for startups to be successful, they will need to demonstrate real value (better clinical outcomes, cost reduction, increased accessibility) and that they can scale.

• Promise of Al Innovation in Improving Workflows and Clinical Outcomes

o In our discussions with industry participants, we were encouraged to see how clinics are increasingly leveraging AI to add efficiency to workflows and improve clinical outcomes. Some areas of note included: embryo selection to better predict implantation, automated imaging and tracking systems to drive more efficiency for embryologists and lab workflow optimization, chatbots and virtual assistants that drive better patient engagement, and leveraging predictive AI to price risk-based fertility financing packages. We are bullish on how AI can play a transformative role in the fertility industry.

Overall, I was encouraged to see the possibility of improved access, greater affordability, more efficiency, and better clinical outcomes. As the industry moves in this direction, I believe we'll see more M&A and capital raising activity in the space. This will include further clinic consolidation to gain scale and efficiencies, clinic diversification strategies to add ancillary capabilities, emerging business models to address access and affordability, and increased venture and growth equity investment in fertility and reprotech companies. If you are interested in hearing more of our perspectives on the women's health and fertility sector, feel free to reach out.

1Fact Sheet: President Donald J. Trump Announces Actions to Lower Costs and Expand Access to In Vitro Fertilization (IVF) and High-Quality Fertility Care - The White House

2 KeyBanc Equity Research

⁴ National Survey of Employer-Sponsored Health Plans



³ Fact Sheet: President Donald J. Trump Announces Actions to Lower Costs and Expand Access to In Vitro Fertilization (IVF) and High-Quality Fertility Care - The White House

M&A Activity

Selected Recent Healthcare Transactions (\$MM)

	Enterprise Value /		se Value /			
Date	Target Name	Acquirer	EV	LTM Rev.	LTM EBITDA	Description
11/7/2025	Infinity Hospice Care	LifeCare Home Health (Zenyth Partners)	NA	NA	NA	Hospice provider serving communities across Nevada and Arizona
11/7/2025	InfuCare Rx (One Equity Partners)	Undisclosed	NA	NA	NA	Provider of specialty infusion therapies at home as well as alternate sites of care
11/6/2025	Arkansas Blue Cross and Blue Shield	Cambia Health Solutions	NA	NA	NA	Health and dental insurance policies for individuals and families as well as insurance coverage through employers
11/4/2025	Always Best Care	NexPhase Capital	NA	NA	NA	Franchisor of in-home senior care services
10/31/2025	Tennova Healthcare JV (Community Health Systems)	Vanderbilt University	\$600	NA	NA	Tennessee based 270-bed hospital and ancillary businesses
10/29/2025	Clario (Astorg, Nordic Capital, Novo and Cinven)	Thermo Fisher Scientific	\$8,875	7.1x	NA	Provider of endpoint data solutions for clinical trials
10/28/2025	Gastro MD (Vesey Street Capital Partners)	United Digestive	NA	NA	NA	Gastroenterology physician practice management organization
10/28/2025	Valley Ambulatory Surgery Center	Duly Health and Care and Surgery Partners	NA	NA	NA	Illinois based multispecialty ambulatory surgery center
10/27/2025	CutisCare (Bison Capital)	RestorixHealth	NA	NA	NA	Multi-place hyperbaric medicine and hospital-based outpatient wound center management services
10/24/2025	Regional Hospital of Scranton, Moses Taylor Hospital, and Wilkes-Barre General Hospital (Community Health Systems)	Tenor Health Foundation*	NA	NA	NA	Pennsylvania based 86-bed Regional Hospital of Scranton and 122-bed Moses Taylor Hospital and 369-bed Wilkes-Barre General Hospital
10/23/2025	Samaritan Health Services	MultiCare Health*	NA	NA	NA	Not-for-profit five hospital system based in Oregon
10/22/2025	HealthEZ (Abry Partners)	Horizon BCBS of New Jersey	\$360	NA	21.0x	Third-party benefits administrator
10/22/2025	Integracare	Frontline Healthcare Partners	NA	NA	NA	Canadian based private-pay home care company
10/21/2025	Hologic	Blackstone and TPG	\$18,300	4.6x	14.5x	Women's health medical technology products, supplies and devices
10/20/2025	LUX Infusion	BioMatrix Infusion Pharmacy (Frazier Healthcare)	NA	NA	NA	Ambulatory infusion center business
10/17/2025	Trinity Health System (CommonSpirit)*	UPMC	NA	NA	NA	Network of hospitals, physician practices, and specialty services across the Ohio Valley
10/17/2025	Legent Health (Strat Cap)	Hospital for Special Surgery and General Atlantic	NA	NA	NA	Operator of orthopedic and spine facilities
10/16/2025	Drive DeVilbiss Healthcare (CD&R)	Kingswood Capital Management	NA	NA	NA	Manufacturer and supplier of essential medical products used primarily in the home setting
10/15/2025	Spring & Bond	Real Chemistry	NA	NA	NA	Digital media agency and consultancy specializing in helping pharmaceutical and medical device manufacturers



Private Placement Activity

Selected Recent Healthcare Transactions (\$MM)

Date	Company	Investor(s)	Туре	Amount	Description
11/6/2025	myLaurel	SteelSky Ventures (lead), Deerfield Management and Google Ventures	Undisclosed	Undisclosed	High-acuity, in-home care for complex and medically fragile patients through a hospital-aligned, tech-enabled model.
11/4/2025	Tala Health	Sofreh Capital (lead)	Undisclosed	\$100	Al company built to empower clinicians with Al agents across the full patient journey
11/3/2025	Hippocratic AI	Avenir Growth (lead), CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children's Hospital Medical Center and WellSpan Health	Series C	\$126	Safety-focused generative AI healthcare agents
10/21/2025	Hyro	Healthier Capital (lead), Norwest and Define Ventures, Bon Secours Mercy Health, ServiceNow Ventures	Growth	\$45	Responsible Al Agent Platform for healthcare
10/16/2025	Brook.ai	UMass Memorial Health and Morningside (co-leads)	Series B	\$28	Remote patient care company focused on Al-enabled patient support and care coordination
10/14/2025	MD Integrations	Updata Partners and Denali Growth Partners	Undisclosed	\$77	End-to-end telehealth platform enabling digital health brands
10/14/2025	Onelmaging	Vy Capital (lead), Aquiline, Sempervirens Venture Capital, XRC Ventures, Dylan Field, Balaji Srinivasan, Jon Oringer and others	Undisclosed	\$38	Tech-enabled radiology platform
10/9/2025	DUOS	FTV Capital (lead) and Forerunner Ventures	Strategic	\$130	Al-enabled digital health platform focused on the senior population
10/9/2025	Sensi.Al	Qumra Capital (lead), Zeev Ventures, Insight Partners, Entrée Capital, Flint Capital, and Jibe Ventures	Series C	\$45	Care intelligence platform that uses audio technology to help older adults age safely at home
10/6/2025	Heidi Health	Point 72 (lead), Blackbird, Headline, and Latitude	Series B	\$65	Al-enabled medical scribe platform for clinical documentation
10/3/2025	Midi Health	Advance Venture Partners (lead)	Series C	\$50	Virtual menopause and perimenopause care company
9/30/2025	Assort Health	Lightspeed Venture Partners (lead), Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet Capital	Series B	\$76	Al-enabled patient communications platform focused on specialty healthcare practices
9/29/2025	Inspiren	Insight Partners (lead), Avenir, Primary Venture Partners, Scale Venture Partners, Story Ventures, Third Prime, and Studio VC	Series D	\$100	Al-enabled solutions company for senior living
9/25/2025	Sunrise Group	Eurazeo (lead), Amazon's Alexa Fund, WE International, Kurma Partners, Vives Fund, Majycc, Namur Invest, Seventure Partners, Investsud, Sambrinvest, Noshaq, IMBC and Invest.BW	Undisclosed	\$29	Digital home based sleep clinic
9/25/2025	Thyme Care	CVS Health® Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures	Series D	\$97	Value-based cancer care enabler
9/24/2025	AmplifyMD	Forerunner Ventures (lead), F-Prime, Greylock, Tau Ventures, and strategic partner Memorial Hermann Health System	Series B	\$20	Integrated virtual care solution
9/23/2025	Judi Health (fka Capital Rx)	Wellington Management and General Catalyst (co-leads), Generation Investment Management, Growth Equity at Goldman Sachs Alternatives, 9Yards Capital, B Capital, Edison Partners, Prime Health Investments, and Transformation Capital	Series F + Additional	\$400	Enterprise health technology company and benefit administrator
9/12/2025	Unmind	Trinity Capital	Growth	\$20	Workplace mental health platform powered by Al
9/11/2025	Diana Health	HealthQuest Capital (lead), Norwest Venture Partners, .406 Ventures, LRVHealth, AlleyCorp	Series C	\$55	Network of women's health practices working in partnership with hospitals
9/9/2025	GEOH	Council Capital	Undisclosed	\$30	Providers of practice management software and services for home care agencies

Equity Capital Markets


Market Overview

- · As we near the end of earnings season, the new issue market remains incredibly resilient:
 - o Last week: 4 IPOs; 9 follow-ons; 9 converts
- Healthcare companies to come to market last week included:
 - o Sotera: Priced a \$471 MM bought deal with Warburg Pincus & GTCR continuing to sell-down their stake
 - o Guardant Health: Priced a concurrent \$345 MM FO & \$403 MM CONV providing flexibility to re-finance its outstanding CB that expires in 2027 and is currently out of the money
 - o BillionToOne: Priced an upsized \$314 MM IPO as investors remained bullish on the pre-natal diagnostics space (comping to Natera which is +50% LTM)


ECM Activity (Last 4 Weeks & YoY)

	2025 - I	_ast 4 W	eeks	2024 - Last 4 Weeks				
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share		
IPO	3,033	6	12%	802	2	2%		
CONV	13,141	13	52%	10,643	8	25%		
FO	9,159	35	36%	30,977	33	73%		
Total	25,333	54	100%	42,422	43	100%		
	2	025 YTD		2024 YTD				
	Vol (\$MM)	# Deals	% Share	Vol (\$MM)	# Deals	% Share		
IPO	31,892	61	14%	26,170	55	12%		
CONV	84,592	106	37%	60,312	80	29%		
FO	109,183	258	48%	123,916	308	59%		

U.S. ECM Offerings (LTM; IPOs, Follow-ons & Converts)



IPO & Follow-on 1-Week Performance (LTM)



Most Recent Healthcare Initial Public Offerings (\$MM)

	Issuer Information				Deal Sizing				Pricing		Performance	
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	% Primary	Offer Price	Final Range	1-Day	1-Week	
11/5/2025	BillionToOne	Diagnostics	BLLN	\$314.0	\$2,724.2	11.5%	100.0%	\$60.00	\$49.00 - \$55.00	81.6%	-	
8/7/2025	Heartflow	Medical Products	HTFL	\$364.2	\$1,531.7	23.8%	100.0%	\$19.00	\$17.00 - \$18.00	51.3%	77.3%	
7/30/2025	Shoulder Innovations	Medical Products	SI	\$75.0	\$303.4	24.7%	100.0%	\$15.00	\$19.00 - \$21.00	0.3%	(12.9%)	
7/22/205	Carlsmed	Medical Products	CARL	\$100.5	\$397.7	25.3%	100.0%	\$15.00	\$14.00 - \$16.00	(3.3%)	(3.3%)	
6/17/2025	Caris Life Sciences	Healthcare Technology	CAI	\$568.2	\$5,836.6	9.7%	100.0%	\$21.00	\$19.00 - \$20.00	33.3%	31.9%	

Most Recent Healthcare Follow-on Offerings (\$MM)

	Issuer Information					Deal Sizing				Perforr	nance
Pricing Date	Company	Sector	Deal Type	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	% Primary	Discount to File	1-Day	1-Week
11/6/2025	Sotera Health	Medical Products	Bought	SHC	\$471.0	\$4,548.3	10.4%	0.0%	(1.9%)	(0.1%)	-
11/4/2025	Guardant Health	Diagnostics	Marketed	GH	\$345.0	\$12,745.9	2.7%	100.0%	(8.3%)	5.6%	-
10/21/2025	Aveanna Healthcare	Services	Marketed	AVAH	\$103.5	\$2,137.2	4.8%	0.0%	(12.0%)	5.3%	9.0%
10/20/2025	Brightspring Health Services	Services	Bought	BTSG	\$435.0	\$5,516.5	7.9%	0.0%	(4.8%)	11.2%	16.7%
9/11/2025	Waystar	Healthcare Technology	Bought	WAY	\$709.2	\$7,056.7	10.1%	0.0%	(2.7%)	(2.7%)	(2.1%)

Most Recent Healthcare Convertible Debt Offerings (\$MM)

	Issu	er Information				Pricing		
Pricing Date	Company	Sector	Ticker	Deal Value (\$MM)	Market Cap (\$MM)	Deal as % of Mkt. Cap	Coupon	Premium
11/4/2025	Guardant Health	Diagnostics	GH	\$402.5	\$12,745.9	3.2%	0.00%	35.00%
9/16/2025	Oscar Health	Health Insurance	OSCR	\$410.0	\$4,842.8	8.5%	2.25%	32.50%
8/19/2025	Evolent Health	Services	EVH	\$145.0	\$1,059.9	13.7%	4.50%	50.00%
6/30/2025	Tempus Al	Healthcare Technology	TEM	\$750.0	\$10,999.8	6.8%	0.75%	32.50%
5/8/2025	Hims & Hers Health*	Healthcare Technology	HIMS	\$1,000.0	\$11,504.9	8.7%	0.00%	37.50%




Public Equity Indices

Equity Indices (as of November 7, 2025)

			Returns		
Index	Wk Open	Wk Close	52 Week	Weekly	
DJIA	47,563	46,987	7.4%	(1.2%)	
S&P 500	6,840	6,729	12.7%	(1.6%)	
NASDAQ	23,725	23,005	19.4%	(3.0%)	
Russell 2000	2,479	2,433	2.1%	(1.9%)	
NYSE Healthcare	25,526	25,235	(10.3%)	(1.1%)	

52 Week 17.3% (13.1%) 5.8%	3.1% (3.3%) (4.2%)
(13.1%)	(3.3%)
5.8%	, ,
	(4.2%)
41.1%	5.7%
6.2%	(2.1%)
39.7%	4.5%
(40.3%)	(2.4%)
0.7%	1.1%
(31.3%)	4.4%
(4.1%)	(3.7%)
38.2%	1.3%
(62.0%)	(17.4%)
8.7%	0.4%
5.9%	0.9%
	39.7% (40.3%) 0.7% (31.3%) (4.1%) 38.2% (62.0%) 8.7%

Cain Brothers Healthcare Indices (1YR Performance)



High Grade, High Yield & Leveraged Loan Market

Market Summary

High Grade

 IG bond markets turned in another large week last week as 36 borrowers tapped the market to raise \$61.2 BN across 67 tranches, more than double the weekly average.


High Yield

 The primary market withstood the negative influence of retail cash outflow in November as 10 issuers priced \$8.9 BN of new issue last week

Term Loan B Market

 CLO issuance has remained strong throughout 2025, and spreads have continued to tighten since September from steady levels seen during the summer.

HY Index Yield & Spread (YTD)



Weekly New Issue Volume (\$BN)



New-Issue Clearing Yields¹ (\$MM)

Double-B Issuers	2Q25	3Q25	30-Day Rolling Average 11/07/25
Ba1	S+265 / 7.1%	S+211 / 6.4%	S+175 / 5.8%
Ba2	S+230 / 6.6%	S+200 / 6.3%	S+220 / 6.4%
Ba3	S+268 / 7.2%	S+241 / 6.7%	S+205 / 6.1%
Single B lecuere	2025	3025	30-Day Rolling Average
Single-B Issuers	2Q25	3Q25	30-Day Rolling Average 11/07/25
Single-B Issuers B1	2Q25 S+317 / 7.7%		
, and the second		S+280 / 7.1%	11/07/25

Most Recent Healthcare High-Grade Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	IPT-Pricing
11/3/2025	Novartis Capital Corp	Sr Notes	\$700	Aa3/AA-/NR	3.900%	11/5/2028	+30	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$800	Aa3/AA-/NR	FRN	11/5/2028	SOFR+52	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$1,750	Aa3/AA-/NR	4.100%	11/5/2030	+45	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$925	Aa3/AA-/NR	4.300%	11/5/2032	+50	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$925	Aa3/AA-/NR	4.600%	11/5/2035	+55	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$350	Aa3/AA-/NR	5.200%	11/5/2045	+55	25 bps
11/3/2025	Novartis Capital Corp	Sr Notes	\$550	Aa3/AA-/NR	5.300%	11/5/2055	+65	25 bps

Most Recent Healthcare High-Yield Issuances (\$MM)

Date	Issuer	Security	Size	Ratings	Coupon	Maturity	Spread	Price Talk
11/3/2025	Tenet Healthcare	Sr. Sec. Notes	\$1,500	Ba3/BB/BB	5.500%	11/15/2032	159 bps	5.50%-5.75%
11/3/2025	Tenet Healthcare	Sr. Notes	\$750	B2/B/BB-	6.000%	11/15/2033	202 bps	6.00%-6.25%

Most Recent Healthcare Leveraged Loan Issuances (\$MM)

Date	issuei	Ownership	Corp. Ratings	Use of Proceeds	Size	Pricing	riela
11/5/2025	Patterson Companies	Patient Square Capital	B2 / B	LBO	\$325	SOFR+450, 0% @ 85	12.242%
10/30/2025	PatientPoint	Not Sponsored	NR / NR	LBO	\$663	SOFR+500, 0% @ 95	10.234%

Most Recent Healthcare Pro Rata Issuances (\$MM)

Date	Issuer	Ownership	Ratings	Use of Proceeds	Size	Pricing (in bps)	Financial Covenants
10/9/2025 Avantor		Public Ba3 / E		Refinancing	\$400mm 5-year Revolver \$1,400mm 5-year Term Loan A	Leverage-based Grid SOFR+150-200 Opens at SOFR+150	Max. First Lien Net Leverage Ratio: 3.50x Min. Interest Coverage Ratio: 2.00x
9/25/2025	SANUWAVE Health	Public	NR / NR	GCP	\$5mm 3-year Revolver \$28mm 5-year Term Loan A	Fixed Spread SOFR+350	Max. Leverage Ratio: 2.50x Min. Fixed Charge Coverage Ratio: 1.25x




Transaction occurred over the past week

Public Finance Market


Market Overview

- The yield on the benchmark 10-year U.S. Treasury Note remained flat week-over-week, closing at 4.11% on Friday. 10-year MMD increased 2 bps week over week
- Healthcare Public Issuance in 2024 increased 143% vs 2023. YTD 2025 Issuance through November 7th was 15% higher than YTD 2024 through the end of November
- Muni bond funds gained \$1.27 BN and high yield funds gained \$277 MM for the week ended November 7th

MMD & UST Yield Curve




Weekly New Issue Volume (\$MM)



Benchmark Yields

Tre	asury Yie	elds	MMD Yields			Ratio		
Yr	Yield	Δ (W/W)	Yr	Yield	Δ (W/W)	MMD/ UST		
2	3.55%	(5 bps)	2	2.46%	-	69%		
10	4.11%	-	10	2.75%	2 bps	67%		
30	4.70%	3 bps	30	4.14%	(1 bps) 88%		

Healthcare Public Issuance Overview



Recent Healthcare Public Issuance

Healthcare Public Issuance ⁽¹⁾										
Borrower/Enhancement	Par (000s)	State	Issuer	Tax Status	LT Ratings (M/S/F)	Final Mat.	Call, Put or Reprice*	Final Mat. Cpn.	YTW	YTM
Recent Pricings, Week of 11/3										
Rush Univ. System for Health	387,425	IL	IFA	TE	A1 / A+ / AA-	2035	NC	5.00%	3.35%	N/A
The Health Care Auth. of Huntsville	160,000	AL	HCACH	TE	A1 / NR / NR	2035	NC	5.00%	3.37%	N/A
The Health Care Auth. of Huntsville	140,000	AL	HCACH	TE	A1 / NR / NR	2055	2026(C)	7.00%	7.00%	N/A
Wesley Commons Project	36,360	SC	SCJEDA	TE	NR / NR / NR	2060	2034(C)	5.63%	5.78%	N/A
Wesley Commons Project	9,200	SC	SCJEDA	TE	NR / NR / NR	2030	NC	3.88%	3.88%	N/A
Exp. Pricings, Week of 11/10										
Horizon House Project	597,330	WA	WSHFC	TE	NR / NR / BB	-	-	-	-	-
Nationwide Children's Hospital	234,190	OH	CFO	TE	Aa2 / NR / AA	-	-	-	-	-
Capitol Lakes, Inc.	99,465	WI	WHEFA	TE	NR / NR / NR	-	-	-	-	-
Uni. Method. Retire. Homes Project	77,620	NC	NCMCC	TE	NR / NR / BBB	-	-	-	-	-
Generous Heart OG Project	26,795	IN	IFA	TE	NR / NR / NR	-	-	-	-	-



Relevant News

To Solve Staffing Shortages, Home-Based Care Must Rethink Recruitment From The Ground Up¹

Home Health Care News | November 2025

Staffing shortages continue to plague the home-based care industry, and traditional recruitment and retention strategies are no longer sufficient. Providers have grappled with the challenge of maintaining a stable workforce, but the current environment—marked by an aging population, restrictive immigration policies, and economic pressures—demands a fundamental shift in how recruitment is approached. While retention remains a critical focus, the industry's recruitment pipelines are drying up. Providers have tried various tactics, including leveraging AI and enhancing employee referral programs, but these efforts alone cannot solve the crisis. The math simply doesn't add up: there aren't enough caregivers to meet the growing demand.

ASCs Focus On Culture, Staffing Flexibility Amid Unprecedented Health Care Leadership Turnover²

Ambulatory Surgery Center News | November 5, 2025

In 2025, ambulatory surgery centers (ASCs) and hospitals are facing a wave of leadership turnover unlike any seen before. Economic pressures, rapid technological change, and evolving workforce expectations have created a volatile environment for healthcare executives. According to Challenger, Gray & Christmas, hospital CEO exits rose nearly 15% year-over-year through July, even as CEO turnover in other industries began to stabilize. Andy Challenger, a workplace expert at the firm, attributes this trend to the immense pressure on leaders to adapt quickly to shifting priorities. Boards are increasingly demanding fresh perspectives and flexibility, leading to a surge in interim appointments. In fact, one-third of new CEO hires in the first half of 2025 were interim, a sharp rise from just 9% in 2024.

Telehealth Advocates Press Congress For Permanent Medicare Virtual Care Policies Amid Shutdown³

Healthcare Dive | November 6, 2025

More than 450 telehealth and provider organizations are pushing lawmakers to avoid another temporary extension of telemedicine flexibilities amid a historic government shutdown. The latest temporary extension of pandemic-era telehealth flexibilities expired at the end of September. These flexibilities, originally introduced during the COVID-19 public health emergency, allowed for broader access to virtual care by removing geographic restrictions and enabling all eligible Medicare providers to offer telehealth services. Prior to the pandemic, Medicare telehealth coverage was largely limited to rural areas and specific services. Despite bipartisan support, these policies have repeatedly faced expiration threats. In December, a bill proposing a longer extension collapsed, resulting in only a short-term fix through March.



Relevant News

Health Groups Urge Passage Of Bill To Ease Medicare Pay Cuts For Tests¹

MedTech Dive | November 3, 2025

More than 30 groups, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests. The RESULTS Act was introduced in September in both the House and Senate with bipartisan support. It aims to reform the CLFS rate-setting process established under the 2014 Protecting Access to Medicare Act, or PAMA, and thereby stop payment reductions of up to 15% that are scheduled to take effect Jan. 1 for about 800 lab tests. Such cuts threaten patient access to routine and life-saving diagnostic tests, the groups said.

CMMI Announces Pilot To Lower Drug Prices In Medicaid²

Healthcare Finance | November 10, 2025

The Centers for Medicare and Medicaid Innovation has released a pilot model designed to lower prescription drug spending in Medicaid. The voluntary model for states, called GENErating cost Reductions fOr U.S. Medicaid (GENEROUS), allows state Medicaid programs to purchase drugs named in the pilot at prices that are the same as those paid in other countries. CMS will be negotiating prices with participating drug manufacturers. This offers more competitive pricing, according to the Centers for Medicare and Medicaid Services. The model launches in 2026. States adopting the model would implement uniform, transparent coverage criteria for consistent standards to give patients and providers predictable access across participating states. CMS said, CMS is releasing a Request for Applications (RFA) for drug manufacturers interested in participating in the GENEROUS Model.

The Benefits Of Integrating A Modern Data Platform Into The EHR³

HealthTech Magazine | November 11, 2025

Healthcare data is rapidly proliferating, much of it generated by electronic health records. To manage and harness all of that data, healthcare systems are increasingly integrating modern, cloud-based data platforms into their EHRs. "Integrating a modern, cloudbased data platform into EHR systems is no longer a luxury, it's a strategic imperative," says Khalid Turk, chief healthcare IT officer for California's Santa Clara County. "Healthcare organizations are dealing with exponential growth in data, and cloud platforms offer the scalability, flexibility and agility needed to manage that effectively."

Recent Cain Brothers Transactions


































Senior Investment Banking Team

Leadership



Wyatt Ritchie
writchie@cainbrothers.com
Group Head

Information Technology



Thad Davis tdavis@cainbrothers.com HealthTech / Digital Health / Services



Jill Frew jfrew@cainbrothers.com Payer Software / Digital Health / B2C



Rishi Soni
rsoni@cainbrothers.com
HealthTech

Life Sciences / MedTech



Carl Hardie chardie@cainbrothers.com Medical Manufacturing & Service Providers



Roman Rezanowicz rrezanowicz@cainbrothers.com Pharma Services & Technology



Jason Moran jmoran@cainbrothers.com Life Sciences Tools & Diagnostics Pharma Services/



Lee Sophocleous

Isophocleous@cainbrothers.com

Pharma Services / CDMOs



Sean Trail strail@cainbrothers.com MedTech Products & Services / Tools & Diagnostics



Mark Webber mwebber@cainbrothers.com MedTech Products & Services

Payers



Mike Elizondo

melizondo@cainbrothers.com

Managed Care / Care Coordination



Stacy Guffanti
sguffanti@cainbrothers.com
Managed & Value-Based Care /
Women's Health



Court Houseworth

chouseworth@cainbrothers.com

Managed Care /

Specialty Managed Care

Providers



Patrick Allen
pallen@cainbrothers.com
Multi-Site / Physician Groups /
Practice Management



Will Brewster
wbrewster@cainbrothers.com
Hospitals & Health Systems



David Cohen dcohen@cainbrothers.com Hospitals & Health Systems



Jeff Danesis jdanesis@cainbrothers.com Multi-Site / Physician Groups



Dan Gold
dgold@cainbrothers.com
Primary & Value-based Care



Andy Goldberg
agoldberg@cainbrothers.com
Distribution / Logistics /



Erika Haanpaa ehaanpaa@cainbrothers.com Behavioral Health



Andy Labovitz

alabovitz@cainbrothers.com

Hospitals & Health Systems



Human Capital Outsourcing

Matthew Margulies

mmargulies@cainbrothers.com

Home Health & Hospice / Pharmacy



Jim Moloney jmoloney@cainbrothers.com Hospitals & Health Systems / Physician Groups



David Morlock dmorlock@cainbrothers.com Hospitals & Health Systems / Physician Groups



Todd Rudsenske trudsenske@cainbrothers.com Behavioral Health / Multi-Site

/ Distribution



Jonah Schutzman jschutzman@cainbrothers.com Physician Practice Management



Mike Tierney mtierney@cainbrothers.com Hospitals & Health Systems



Jenny Watson jwatson@cainbrothers.com Dental / Health & Beauty

Healthcare Product Partners



Mark Barath
mbarath@key.com
Equity Capital Markets



Carl McCarden cmccarden@key.com Sponsor Coverage



Ryan Stilphen
ryan.stilphen@key.com
Leveraged Finance



Igor Vinogradov ivinogradov@key.com Lending / Banking Products



Senior Public Finance Team



Bart Plank
bplank@cainbrothers.com



Kyle Hemminger *khemminger*@*cainbrothers.com*



Dominic Porretta dporretta@cainbrothers.com



Kathy Kirchhoff
kkirchhoff@cainbrothers.com



Taaha Shaikh tshaikh@cainbrothers.com



James Conahan jconahan@cainbrothers.com



Joe Mulligan jmulligan@cainbrothers.com



Joanna Stephenson jstephenson@cainbrothers.com



Maura Davalos mdavalos@cainbrothers.com



Joe Pollock jpollock@cainbrothers.com

Industry Insights is compiled weekly by Cain Brothers, 1301 Avenue of the Americas, 37th Floor, New York, NY 10019 Ph: (212) 869-5600. To receive our Industry Insights email, please register on. For questions regarding Industry Insights please email rgruber@cainbrothers.com

The information contained in this report was obtained from various sources, including third parties, that we believe to be reliable, but neither we nor such third parties guarantee its accuracy or completeness. Additional information is available upon request. The information and opinions contained in this report speak only as of the date of this report and are subject to change without notice. This report has been prepared and circulated for general information only and presents the authors' views of general market and economic conditions and specific industries and/or sectors. This report is not intended to and does not provide a recommendation with respect to any security. Cain Brothers, a division of KeyBanc Capital Markets ("Cain Brothers"), as well as any third-party information providers, expressly disclaim any and all liability in connection with any use of this report or the information contained therein. Any discussion of particular topics is not meant to be comprehensive and may be subject to change. This report does not take into account the financial position or particular needs or investment objectives of any individual or entity. The investment strategies, if any, discussed in this report may not be suitable for all investors. This report does not constitute an offer, or a solicitation of an offer to buy or sell any securities or other financial instruments, including any securities mentioned in this report. Nothing in this report constitutes or should be construed to be accounting, tax, investment or legal advice. Neither this report, nor any portions thereof, may be reproduced or redistributed by any person for any purpose without the written consent of Cain Brothers and, if applicable, the written consent of any third-party information provider.

"Cain Brothers, a division of KeyBanc Capital Markets" is a trade name of KeyBanc Capital Markets Inc., Member FINRA/SIPC.

KeyBanc Capital Markets Inc. and KeyBank National Association (""KeyBank N.A."") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives. Banking products and services are offered by KeyBank N.A. ©2025 KeyCorp®. All rights reserved.

